Modern Medicine News
NCPA has asked congressional leaders to look into the reasons behind the skyrocketing costs of generic drugs.
A draft review sponsored by the Agency for Healthcare Research and Quality (AHRQ) found insufficient evidence for medication therapy management (MTM) effect on most outcomes.
Aurobindo, Dr. Reddy’s, Lupin, Sun Pharma, Teva, and Torrent Pharmaceuticals all received the OK.
Presented during the Midyear Clinical 2013 Meeting, the report, based on a survey of of 164 industry experts, outlines key trends developing in hospital pharmacy.
WAG–Boots–Amerisource Bergen was only the first. Here comes another behemoth.
Stakeholders meeting in Washington, D.C., discussed funding, costs, challenges, and directions.
Study showed lower doses less effective.